Table 2.

Clinical outcome data for the 3 STP components individually or in combination

	PKCα			ERK2 & pERK2					pAKT			PKCa-ERK2&pERK2-pAKT
	Low	High	P	Low-low	Low-high	High-low	High-high	P	Low	High	P	None	1 high	2 + high	3 + high	P
No. of patients	89	99	—	47	15	76	50	—	78	70	18	44	39	45	—
Response	.14	.69	—	.55
CR	60%	49%	60%	53%	57%	48%	60%	50%	.21	56%	59%	64%	49%
Fail	8%	15%	6%	13%	16%	12%	8%	16%	0%	11%	10%	16%
Resistant	31%	35%	34%	33%	28%	40%	32%	34%	44%	30%	26%	36%
Relapse	51%	63%	.21	57%	38%	60%	54%	.68	51%	54%	.77	40%	46%	52%	64%	.55
Median CR duration, wk	50	45	.1	63.4	107.7	37.8	57.1	.3	72.57	40.3	.13	76.4	71.57	53.3	25.7	.125
Median survival, wk	59	34	.02	72	39	38.5	30.93	.05	61.21	29.85	.028	78.57	57.86	42.3	23.4	.012
Alive	38%	27%	—	47%	27%	28%	28%	—	42%	27%	—	61%	39%	33%	24%	—
Median follow-up, wk	112	134.5	—	153	135	88	121	—	135.6	104	—	152	106	104	104	—

— indicates not applicable.